Approximately 10% of amyotrophic lateral sclerosis (ALS) cases are familial (known as FALS) with an autosomal dominant inheritance pattern, and~25% of FALS cases are caused by mutations in Cu/Zn superoxide dismutase (SOD1). There is convincing evidence that mutant SOD1 (mtSOD1) kills motor neurons (MNs) because of a gain-of-function toxicity, most likely related to aggregation of mtSOD1. A number of recent reports have suggested that antibodies can be used to treat mtSOD1-induced FALS. To follow up on the use of antibodies as potential therapeutics, we generated single chain fragments of variable region antibodies (scFvs) against SOD1, and then expressed them as 'intrabodies' within a motor neuron cell line. In the present study, we describe isolation of human scFvs that interfere with mtSOD1 in vitro aggregation and toxicity. These scFvs may have therapeutic potential in sporadic ALS, as well as FALS, given that sporadic ALS may also involve abnormalities in the SOD1 protein or activity.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the selective loss of motor neurons (MNs). Approximately 10% of ALS cases are familial (known as FALS) with an autosomal dominant inheritance pattern, and~25% of FALS cases are caused by mutations in Cu/Zn superoxide dismutase (SOD1) (Rothstein, 2009) . There is convincing evidence that mutant SOD1 (mtSOD1) kills motor neurons (MNs) because of a gain-of-function, rather than a loss-of-function (i.e., a loss of dismutase activity). Although the nature of the mtSOD1 toxicity remains unclear, some investigators have postulated a key role played by aggregation of mtSOD1, with an associated sequestration of proteins that are critical for the viability of the MN. Such sequestration of proteins could lead to a variety of other deficits, such as abnormalities in axonal flow and alterations in the endoplasmic reticulum stress pathway.
Of interest, recent data suggest that sporadic ALS may also involve abnormalities in the SOD1 protein or activity (Bosco et al., 2010; Ezzi et al., 2007; Guareschi et al., 2012; Kabashi et al., 2007; Pokrishevsky et al., 2012) . Therefore, investigations of mtSOD1 may not only clarify our understanding of the pathogenesis and the treatment of FALS, but also increase our understanding and treatment of sporadic ALS.
A number of reports have suggested that antibodies may have a role in the treatment of mtSOD-1-induced FALS. Immunization with mtSOD1 protein (Takeuchi et al., 2010; Urushitani et al., 2007) or a peptide within the SOD1 interface (Liu et al., 2012) delays disease onset and extends survival of FALS transgenic mice. Furthermore, Alzet osmotic minipump intraventricular infusion of anti-SOD1 monoclonal antibodies (mAbs) into FALS transgenic mice delays body weight loss and hind limb reflex impairment and significantly prolongs survival (Gros-Louis et al., 2010; Urushitani et al., 2007) . Together, these studies demonstrate that anti-SOD1 antibodies can ameliorate disease in FALS transgenic mice.
In the present study, we describe isolation of single chain fragments of variable regions (scFvs) of antibodies directed against SOD1, focusing on two scFvs that interfere with in vitro aggregation and toxicity of mtSOD1. One of the advantages of scFvs is that they can be readily cloned, expressed, and used in gene delivery studies. Of special interest, scFvs can be expressed within cells, where these "intrabodies" can bind to and perturb their targets (Zu et al., 1997 
